InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: swampboots post# 928

Wednesday, 08/03/2022 12:21:22 PM

Wednesday, August 03, 2022 12:21:22 PM

Post# of 932
The collab is focused on advancing multiple existing and additional next gen allo CAR-T programs directed to haematological malignancies. RHHBY has an exclusive license to anti-BCMA and anti-CD19/CD20 programs. Exclusive option to anti-CD70 and anti-BCMA/CD19 programs, as well as the right to nominate six additional candidates.